Replies to post #567870 on ORIONS Money Stocks

[stock1ace1]

Abeo $3.11 pending phase 3 news 3 mill float 5 mill o/s

Topline data from the Phase 3 VIITAL™ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 upon completion of the last patient monitoring visit, which is expected by mid-September.

With Ultragenyx assuming all financial responsibility for the continued development of ABO-102, we were able to extend our cash runway well beyond the VIITAL data readout. The additional runway puts us in a strong position to forge the optimal commercial partnership that fully appreciates

[stock1ace1]

Abeo $3.20s up only 3 mill float